generic insulin. This was the impetus in Pfizer's recent purchase of Bioconn. The opportunity for the broader set of insulin properties is vast. The Lantus product is key and growth rates are notable. We can provide a truly affordable version and safely compete in the market. The key is to understand t

its/ml) 10ml vial of beef insulin (100 units/ml) 10ml vial •f beef/pork insulin (100 units/ml) 10ml vial of beef insulin (40 units/ml) Lantus Bangladesh 4.5 3.6 15.6 Belarus 9.0 2.9 0.9 China 9.0 5.0 0.7 0.3 Con•o 34.0 2.1 C8te 10.0 1.0 Mongolia 10.0 8.0 0.5 Nigeria

er can come in for duration of IP (18 years) • Analytical tools and capabilities to support protein therapeutics in other areas Generic Insulin Lantus Humalog Novalog Glucagon Manufacturing IP is the center of the patent estate and a full suite of patents have been filed and issued globally cel